JP2016512198A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512198A5
JP2016512198A5 JP2015561594A JP2015561594A JP2016512198A5 JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5 JP 2015561594 A JP2015561594 A JP 2015561594A JP 2015561594 A JP2015561594 A JP 2015561594A JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5
Authority
JP
Japan
Prior art keywords
independently selected
group
optionally substituted
hydrogen
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512198A (ja
JP6318180B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020700 external-priority patent/WO2014138212A1/en
Publication of JP2016512198A publication Critical patent/JP2016512198A/ja
Publication of JP2016512198A5 publication Critical patent/JP2016512198A5/ja
Application granted granted Critical
Publication of JP6318180B2 publication Critical patent/JP6318180B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561594A 2013-03-06 2014-03-05 CaMKII阻害剤及びその使用 Expired - Fee Related JP6318180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773779P 2013-03-06 2013-03-06
US61/773,779 2013-03-06
PCT/US2014/020700 WO2014138212A1 (en) 2013-03-06 2014-03-05 CaMKII INHIBITORS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2016512198A JP2016512198A (ja) 2016-04-25
JP2016512198A5 true JP2016512198A5 (cg-RX-API-DMAC7.html) 2017-04-06
JP6318180B2 JP6318180B2 (ja) 2018-04-25

Family

ID=51491905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561594A Expired - Fee Related JP6318180B2 (ja) 2013-03-06 2014-03-05 CaMKII阻害剤及びその使用

Country Status (7)

Country Link
US (1) US9951061B2 (cg-RX-API-DMAC7.html)
EP (1) EP2964225B1 (cg-RX-API-DMAC7.html)
JP (1) JP6318180B2 (cg-RX-API-DMAC7.html)
CN (1) CN105517549B (cg-RX-API-DMAC7.html)
AU (1) AU2014225889B2 (cg-RX-API-DMAC7.html)
CA (1) CA2901155C (cg-RX-API-DMAC7.html)
WO (1) WO2014138212A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037106A1 (en) * 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc CaMKII INHIBITORS AND USES THEREOF
JP6532737B2 (ja) * 2015-04-01 2019-06-19 東ソー・ファインケム株式会社 ヘテロアセン化合物の製造方法
AR110252A1 (es) * 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
KR20200027521A (ko) * 2017-07-06 2020-03-12 칠드런'즈 메디컬 센터 코포레이션 카테콜아민성 다형성 심실성 빈맥을 치료하거나 예방하기 위한 조성물 및 방법
MX2020008581A (es) 2018-02-21 2020-09-21 Bristol Myers Squibb Co Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
WO2024197267A1 (en) * 2023-03-22 2024-09-26 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of ca 2+/calmodulin-dependent protein kinase ii (camkii) that do not inhibit long-term potentiation (ltp) induction and therapeutic uses thereof
WO2025101615A1 (en) * 2023-11-07 2025-05-15 Cardurion Pharmaceuticals, Inc. Polymorphs of a pyridinylimidazo[1,2-b]pyridazine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033491A2 (en) 1997-01-31 1998-08-06 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
NZ532327A (en) 2001-10-01 2005-10-28 Univ Vanderbilt Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
WO2006007422A2 (en) * 2004-06-16 2006-01-19 The Trustees Fo Columbia University In The City Of New York CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS
JPWO2006049215A1 (ja) 2004-11-02 2008-05-29 大日本住友製薬株式会社 自己免疫疾患を治療するための併用薬
CN101218241B (zh) 2005-05-16 2011-02-16 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2006131552A1 (de) * 2005-06-09 2006-12-14 Boehringer Ingelheim International Gmbh Alpha-carboline als cdk-1 inhibitoren
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2016512198A5 (cg-RX-API-DMAC7.html)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2013010792A5 (cg-RX-API-DMAC7.html)
JP2017534572A5 (cg-RX-API-DMAC7.html)
JP2016538257A5 (cg-RX-API-DMAC7.html)
JP2013545730A5 (cg-RX-API-DMAC7.html)
WO2015191506A3 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
JP2019524897A5 (cg-RX-API-DMAC7.html)
JP2010511701A5 (cg-RX-API-DMAC7.html)
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
SA109300394B1 (ar) ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP2011518168A5 (cg-RX-API-DMAC7.html)
JP2022523702A (ja) トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
CO6341628A2 (es) \\\\\\\"nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imegenes de depositos amiloides\\\\\\\"
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2015522592A5 (cg-RX-API-DMAC7.html)
JP2015515496A5 (cg-RX-API-DMAC7.html)
CN106458878B (zh) 2-氰基-3-环丙基-3-羟基-n-芳基-硫代丙烯酰胺衍生物
RU2013107659A (ru) ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε
US20220411398A1 (en) Jnk inhibitors as anticancer agents
ES2531437T3 (es) Docosahexaenoato de pantenilo y su utilización para el tratamiento y la prevención de las enfermedades cardiovasculares
JP4964593B2 (ja) 神経学的病状の治療用のテトラヒドロインドロン誘導体
CN104321323A (zh) 碳环核苷及其医药用途和组合物